What Happened?
Shares of health insurance company Oscar Health (NYSE: OSCR) fell 3.7% in the morning session after the stock's momentum weakened as its President of Technology & CTO, Mario Schlosser, sold a significant amount of company stock.
According to a filing, Schlosser sold 395,000 shares on September 22, 2025, for a total value of approximately $7.28 million. Large stock sales by high-level executives can sometimes worry investors, as they may be interpreted as a sign of weakening confidence in the company's future performance.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Oscar Health? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Oscar Health’s shares are extremely volatile and have had 66 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 8 days ago when the stock dropped 4.6% on the news that the stock's negative momentum continued as the company announced it is offering $355 million in convertible senior notes and received a downgrade from a Wall Street analyst.
The debt offering, a common way for companies to raise cash, sparked concerns about potential dilution for existing shareholders. This can happen because the notes can be converted into the company's stock in the future, which increases the total share count. The notes, which mature in 2030, carried an interest rate of 2.25% per year. Oscar Health stated the proceeds would be used for general corporate purposes and to fund AI-driven initiatives. Compounding the negative sentiment, Barclays analyst Steve Valiquette downgraded Oscar Health's stock from “Equal Weight” to “Underweight,” citing concerns about the company's path to profitability.
Oscar Health is up 30.8% since the beginning of the year, but at $17.72 per share, it is still trading 17.9% below its 52-week high of $21.58 from September 2024. Investors who bought $1,000 worth of Oscar Health’s shares at the IPO in March 2021 would now be looking at an investment worth $509.20.
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
